News & Insights

Peer-credible reporting on peptide science, regulation, and the research community. No hype. No therapeutic claims.

Regulatory
Featured · May 12, 2026

FDA's 2025 Crackdown on Compounded GLP-1s: What It Means for Research Access

As the agency restores brand-name semaglutide and tirzepatide to its supply list, compounding pharmacies face new constraints — and researchers brace for downstream effects.

MC
Mara Costa
4 min read
Read the full report
Talk to our ambassador
on WhatsApp